Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell

BioAge Labs (NASDAQ:BIOA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other brokerages have also issued reports on BIOA. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Citigroup upped their target price on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.00.

BioAge Labs Price Performance

BioAge Labs stock opened at $14.03 on Friday. The firm has a market cap of $502.98 million, a P/E ratio of -9.23 and a beta of 1.38. BioAge Labs has a fifty-two week low of $2.88 and a fifty-two week high of $16.43. The firm has a 50 day moving average of $10.90.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $2.05 million during the quarter.

Insider Buying and Selling at BioAge Labs

In other news, insider Paul D. Rubin sold 18,000 shares of BioAge Labs stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total transaction of $216,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 20.82% of the company’s stock.

Institutional Trading of BioAge Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of BioAge Labs during the 2nd quarter worth about $27,000. Russell Investments Group Ltd. acquired a new position in BioAge Labs in the third quarter valued at approximately $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in BioAge Labs in the second quarter valued at approximately $57,000. Finally, Intech Investment Management LLC acquired a new stake in BioAge Labs during the second quarter worth approximately $60,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.